All News

This morning, Senate Republican leaders released the draft of a bill to repeal and replace the Affordable Care Act (Obamacare).

Inhibiting the ABCB1 gene with antiandrogen therapy – such as Xtandi (enzalutamide) and Casodex (bicalutamide) – may be the answer to increasing efficiency of tanxane-based therapies.

A recent study found that the level of family caregiver mastery may have an effect on the survival of patients with glioblastoma.

Finding relief from the painful condition of lymphedema is a challenge, but there is research that using weights may help.

Chances are you or someone you know and love has been touched by heart disease and cancer survivors are at even greater risk.

New studies have confirmed that loneliness can be very bad for health.

Expert Lisa G. Roth, M.D., discusses the unique needs of AYA patients with Hodgkin lymphoma.

​Joseph Greer, Ph.D., Clinical Director of Psychology and Research Scientist in the Center for Psychiatric Oncology & Behavioral Sciences at Massachusetts General Hospital, explains a mobile app to help anxiety in patients who have incurable cancer.

Cabometyx had better progression-free survival rates than Sutent (sunitinib) for certain patients with renal cell carcinoma.

Prosthesis ups and downs.

Every person recalls vividly when they were given the diagnosis of cancer.

Accepting what is fact and being OK with the reality of an awful illness

A drug combination is showing promise in mouse models and may lead to a new treatment option for patients with glioblastoma.

Imfinzi (durvalumab) may change the treatment paradigm for some patients with urothelial carcinoma.

A recently-published Canadian study examined the possible correlation between work-related stress and cancer.

This is probably not about what you’re thinking.

Being able to laugh during difficult situations is a good thing especially for those who've suffered the trauma of breast cancer. Here's one woman's experience learning to laugh at the loss of her breasts.

Kale is incredibly popular. It's everywhere.

JCAR017 had promising complete response and objective response rates in treating patients with diffuse large B-cell lymphoma (DLBCL) in a recently presented study.

Reforms are needed high up within the drug distribution chain, concluded a panel of pharmaceutical professionals at the Oncology Market Access & Pricing conference held in Philadelphia this week by eyeforpharma.

There is hot debate over whether full-body skin exams should be done each year to help in early detection of both non-melanoma and melanoma skin cancers.

How decreasing my pace has made me acutely aware of the outside noise that distracts us from the life’s most important things, which aren’t things at all.

Green can be a beautiful color full of life, but it can also be the color of chemotherapy.

Apreciating all the positives amongst the disease of cancer

Three times comments about my cancer made me say, "Huh?"

The Food and Drug Administration (FDA) granted an approval to Darzalex (daratumumab) for use in combination with Pomalyst (pomalidomide) and dexamethasone for patients who have multiple myeloma who have two or more prior therapies, including a proteasome inhibitor and Revlimid (lenalidomide).

Opdivo had promising response rates in a recent trial testing the treatment in patients with relapsed or refractory Hodgkin lymphoma.

Taking the good with the bad and living life despite cancer